Last reviewed · How we verify

PRAZIQUANTEL — Competitive Intelligence Brief

PRAZIQUANTEL (PRAZIQUANTEL) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Anthelmintic [EPC].

marketed Anthelmintic [EPC] Small molecule Live · refreshed every 30 min

Target snapshot

PRAZIQUANTEL (PRAZIQUANTEL).

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
PRAZIQUANTEL TARGET PRAZIQUANTEL marketed Anthelmintic [EPC] 1982-01-01
Egaten TRICLABENDAZOLE Novartis marketed Anthelmintic [EPC] Transthyretin 2019-01-01
Albenza ALBENDAZOLE Impax Labs Inc marketed Anthelmintic [EPC] 1996-01-01
(+/-)-Oxamniquine OXAMNIQUINE marketed Anthelmintic 1980-01-01
Vermox MEBENDAZOLE marketed Anthelmintic [EPC] Vascular endothelial growth factor receptor 2 1974-01-01
Bovizole THIABENDAZOLE marketed Anthelmintic Cytochrome P450 1A2 1967-01-01
Caricide DIETHYLCARBAMAZINE Pfizer marketed Anthelmintic Arachidonate 5-lipoxygenase 1950-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Anthelmintic [EPC] class)

  1. · 2 drugs in this class
  2. Impax Labs Inc · 1 drug in this class
  3. Novartis · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). PRAZIQUANTEL — Competitive Intelligence Brief. https://druglandscape.com/ci/praziquantel. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators: